<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153150</url>
  </required_header>
  <id_info>
    <org_study_id>SoSTART2016</org_study_id>
    <secondary_id>2016-004121-16</secondary_id>
    <nct_id>NCT03153150</nct_id>
  </id_info>
  <brief_title>Start or STop Anticoagulants Randomised Trial (SoSTART)</brief_title>
  <acronym>SoSTART</acronym>
  <official_title>Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic
      intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does
      starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction
      of all serious vascular events compared with not starting OAC?

      Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel
      group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies.
      Investigators plan for a pilot phase, followed by a safety phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bleeding within the skull, also known as brain haemorrhage, affects 3 million people in the
      world each year.

      One in five people who survive brain haemorrhage have an irregular heart rhythm called
      'atrial fibrillation', which puts them at risk of stroke and other blood clots.

      Blood-thinning medicines, known as 'anticoagulant' drugs, are used in everyday clinical
      practice to protect people with atrial fibrillation from developing blood clots. However,
      these drugs also increase the risk of bleeding and are usually stopped when the brain
      haemorrhage occurs.

      But when patients recover from brain haemorrhage, they and their doctors are often uncertain
      about whether to start or stop these drugs to prevent further clots occurring, or whether to
      avoid them in case they increase the risk of brain haemorrhage happening again.

      Investigators want to find out whether starting or not starting an anticoagulant drugs is
      better for those patients.

      A network of hospital doctors, nurses, and other staff will identify people who survive brain
      haemorrhage and have atrial fibrillation. If a patient and their doctor are uncertain about
      whether to start an anticoagulant drug, they may invite the patient to participate.

      In the pilot phase, investigators aim to recruit at least 60 participants to determine the
      feasibility of recruiting the target sample size of at least 190 participants in the safety
      phase of the trial.

      Investigators will follow-up all participants for at least one year to determine whether
      prescribing an anticoagulant drug reduces the occurrence of all serious vascular events like
      heart attack, stroke compared with a policy of avoiding oral anticoagulant.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 allocation of intervention: comparator, using a minimisation algorithm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants recruited per site per month (in the pilot phase of the trial)</measure>
    <time_frame>1 year after trial initiation</time_frame>
    <description>The rate of recruiting up to 60 participants to determine the feasibility of recruiting the target sample size in the main phase of the trial in an acceptable timescale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent symptomatic spontaneous intracranial haemorrhage (in the safety phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>~60 hospital sites will recruit at least 190 participants to determine whether the risk of recurrent symptomatic intracranial haemorrhage is sufficiently low (non-inferior) to justify a definitive trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportions of all eligible patients recorded on screening logs who are recruited, unsuitable, or decline to participate (in the pilot phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>The acceptability of the trial protocol to investigators and patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of Symptomatic serious vascular events: (in the safety phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>• All symptomatic serious vascular events (i.e. major adverse cardiac or cerebrovascular events [MACCE]) including: non-fatal (i.e. not followed by death within 30 days of onset) myocardial infarction; stroke (i.e. ischaemic, haemorrhagic, unknown sub-type) or spontaneous subdural haemorrhage; or death from a vascular cause (i.e. haemorrhagic or ischaemic events followed by death within 30 days), sudden death, or death of an unknown cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>The number of Individual symptomatic vascular events: (in the safety phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>Major haemorrhagic events (Bleeding Academic Research Consortium types 3-5)
Recurrent symptomatic spontaneous intracranial haemorrhage
Extracranial haemorrhage
Symptomatic ischaemic events
ischaemic stroke
myocardial infarction
peripheral arterial occlusion
mesenteric ischaemia
central retinal arterial occlusion
deep vein thrombosis
pulmonary embolism
cardiac death with symptoms suggestive of myocardial ischaemia (type 3),or evidence of arrhythmia
Revascularisation procedures (carotid, coronary, or peripheral arterial)
Symptomatic stroke of uncertain sub-type
Non-fatal stroke, with brain imaging performed too late to distinguish haemorrhage from infarction
Rapidly fatal stroke, but without radiographic or pathological confirmation</description>
  </other_outcome>
  <other_outcome>
    <measure>Annual ratings of participant dependence completed by participant, their carer or nominated contact, or healthcare provider (e.g. general practitioner):</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>• Simplified modified Rankin Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Ratings of participant quality of life completed by participant, their carer or or nominated contact</measure>
    <time_frame>Randomisation and 1 year after randomisation</time_frame>
    <description>• The 5-level EQ-5D version (EQ-5D-5L) of the EuroQol</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Intracranial Hemorrhages</condition>
  <condition>Intracranial Hemorrhage, Hypertensive</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Subdural Hematoma</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Small Vessel Cerebrovascular Disease</condition>
  <condition>Microhaemorrhage</condition>
  <arm_group>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the patient is randomized in this arm, an oral anticoagulant:
Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or
Direct thrombin inhibitor: Dabigatran or
Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Do not start oral anticoagulant (OAC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:
antiplatelet drug(s) or
no antithrombotic drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acenocoumarol</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Sinthrome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenindione</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Dindevan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Marevan</other_name>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age ≥18 years

          2. Symptomatic intracranial haemorrhage (i.e. intracerebral haemorrhage, non-aneurysmal
             subarachnoid haemorrhage,intraventricular haemorrhage, or subduralhaemorrhage)

               -  Not attributable to a known underlying intracranial aneurysm, arteriovenous
                  malformation, cerebral cavernous malformation, dural arteriovenous fistula,
                  intracranial venous thrombosis

               -  Not attributable to known head injury, based on:

               -  a history from the patient/witness of spontaneous symptom onset without preceding
                  head trauma (head trauma occurring after symptom onset is permissible)

               -  brain imaging appearances consistent with spontaneous intracranial haemorrhage
                  (which may be accompanied by the brain/bone/soft tissue appearances of trauma
                  occurring subsequently)

          3. Atrial fibrillation/flutter (persistent or paroxysmal) with a CHA2DS2-VASc score ≥2

          4. If included in the brain magnetic resonance imaging (MRI) sub-study, the scan must be
             done after symptomatic intracranial haemorrhage and before randomisation

        Exclusion Criteria:

          1. Symptomatic intracranial haemorrhage within the last 24 hours (when the risk of
             haemorrhage expansion/growth is greatest)

          2. Symptomatic intracranial haemorrhage is exclusively due to trauma or haemorrhagic
             transformation of ischaemic stroke

          3. Prosthetic mechanical heart valve or severe (haemodynamically significant) native
             valve disease

          4. Left atrial appendage occlusion for prevention of systemic embolism in AF done in the
             past, or intended to be performed

          5. Intention to start antiplatelet drug(s) if randomised to start full dose OAC

          6. Intention to start OAC or parenteral anticoagulation

          7. Intention to implement the allocated treatment strategy for &lt;1 year

          8. Patient or their doctor is certain about whether to start or avoid full dose OAC

          9. Brain imaging that first diagnosed the intracranial haemorrhage is not available

         10. Patient is not registered with a general practitioner

         11. Patient is pregnant, breastfeeding, or of childbearing age and not taking
             contraception

         12. Patient and carer unable to understand spoken or written English

         13. Contraindications to any of the IMPs, other than recent intracranial haemorrhage

         14. Contraindication to MRI (brain MRI sub-study)

         15. Life expectancy less than one year

         16. Previously randomised in SoSTART
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rustam Al-Shahi Salman, MA PhD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevill Hall Hospital</name>
      <address>
        <city>Abergavenny</city>
        <zip>NP7 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Hospital</name>
      <address>
        <city>Barnet</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales/ /University Hospital Llandough</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derby Royal Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Hospital</name>
      <address>
        <city>Derry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital North Durham</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West Acute Hospital</name>
      <address>
        <city>Enniskillen</city>
        <zip>BT74 6DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Gateshead</city>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calderdale Royal Hospital</name>
      <address>
        <city>Halifax</city>
        <zip>HX3 0PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ystrad Mynach Hospital</name>
      <address>
        <city>Hengoed</city>
        <zip>CF82 7EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital Kirkcaldy</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS13EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L78XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7 AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 OQT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luton &amp; Dunstable University Hospital</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's Mill Hospital</name>
      <address>
        <city>Mansfield</city>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <zip>PE3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poole Hospital</name>
      <address>
        <city>Poole</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen' Hospital Romford</name>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Princess Royal Hospital</name>
      <address>
        <city>Telford</city>
        <zip>TF1 6TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay District General Hospital</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-on-Sea</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hampshire County Hospital</name>
      <address>
        <city>Winchester</city>
        <zip>SO22 5DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <zip>CH49 5EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sostart.ed.ac.uk</url>
    <description>Trial website</description>
  </link>
  <link>
    <url>http://www.rush.ed.ac.uk</url>
    <description>Chief investigator details</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral anticoagulant</keyword>
  <keyword>Factor Xa inhibitors</keyword>
  <keyword>Direct thrombin inhibitor</keyword>
  <keyword>Vitamin K antagonist</keyword>
  <keyword>Antiplatelet drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
    <mesh_term>Phenindione</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Chief Investigator (Prof. Rustam Al-Shahi Salman) has established the Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH) working towards a pre-planned individual patient data meta-analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

